World's Best Scientists 2026 revealed!
Andrew M. Scott

Andrew M. Scott

D-Index & Metrics

Medicine

D-Index
102
Citations
35066
World Ranking
7714
National Ranking
229

Overview

Andrew M. Scott is affiliated with La Trobe University in Australia. Their research primarily centers on the field of Medicine, with a notable focus on Radiology, Nuclear Medicine and Imaging, and Oncology. Other areas of study include Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

The scientist's work extensively addresses topics such as Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications, Radiomics and Machine Learning in Medical Imaging, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, and HER2/EGFR in Cancer Research.

Frequent collaboration is evident with co-authors including Hui Gan, Sze Ting Lee, Ingrid J.G. Burvenich, Angela Rigopoulos, and Roslyn J. Francis. These partnerships have contributed to a substantial body of research.

Andrew M. Scott has published in various scientific journals with significant publication counts in these venues:

  • European Journal of Nuclear Medicine and Molecular Imaging
  • The Lancet Oncology
  • Journal of Nuclear Medicine
  • Nature Middle East
  • Cancers

Some recent notable publications include:

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial (2021, The Lancet)
  • Antibody-Drug Conjugates for Cancer Therapy (2020, Molecules)
  • Radiotheranostics in oncology: current challenges and emerging opportunities (2022, Nature Reviews Clinical Oncology)
  • Medical imaging and nuclear medicine: a Lancet Oncology Commission (2021, The Lancet Oncology)
  • PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial (2022, The Lancet Oncology)

Best Publications

  • Antibody therapy of cancer

    Andrew M. Scott;Jedd D. Wolchok;Lloyd J. Old;Lloyd J. Old

  • Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.

    Bow J. Tauro;David W. Greening;Rommel A. Mathias;Hong Ji

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

    Michael S Hofman;Louise Emmett;Shahneen Sandhu;Amir Iravani

  • A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

    Andrew M Scott;Greg Wiseman;Sydney Welt;Alex Adjei

  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

    Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

  • Monoclonal antibodies in cancer therapy

    Andrew M. Scott;James P. Allison;Jedd D. Wolchok;Jedd D. Wolchok

  • Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

    David S. Ritchie;Paul J. Neeson;Paul J. Neeson;Amit Khot;Stefan Peinert

  • Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole

    Sze Ting Lee;Andrew M. Scott;Andrew M. Scott

  • Bridging Bio-Nano Science and Cancer Nanomedicine

    Mattias Björnmalm;Kristofer J. Thurecht;Michael Michael;Andrew M. Scott

  • Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma

    Ian C. Nicholson;Kelly A. Lenton;Debbie J. Little;Tina Decorso

  • The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

    Paul J. Roach;Roslyn Francis;Louise Emmett;Edward Hsiao

  • Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

    S Welt;C R Divgi;A M Scott;P Garin-Chesa

  • Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor

    Kazuhiko Mishima;Terrance G. Johns;Rodney B. Luwor;Andrew M. Scott

  • Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

    S Welt;A M Scott;C R Divgi;N E Kemeny

  • A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

    Andrew M Scott;Fook-Thean Lee;Niall Tebbutt;Rebecca Herbertson

  • The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.

    John D Kiffer;Salvatore U Berlangieri;Andrew M Scott;George Quong

  • Antibody–Drug Conjugates for Cancer Therapy

    Umbreen Hafeez;Umbreen Hafeez;Sagun Parakh;Sagun Parakh;Hui K Gan;Andrew M Scott

  • CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA

    Shakher Ramdave;Gwynne W. Thomas;Salvatore U. Berlangieri;Damien M. Bolton

  • A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

    Achim A Jungbluth;Elisabeth Stockert;H J Su Huang;Vincent P Collins

  • The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily

    Joan K. Heath;Sara J. White;Cameron N. Johnstone;Bruno Catimel

Frequent Co-Authors

Ian D. Davis
Ian D. Davis Monash University
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
Terrance Grant Johns
Terrance Grant Johns Telethon Kids Institute
Antony W. Burgess
Antony W. Burgess Walter and Eliza Hall Institute of Medical Research
Nathan Lawrentschuk
Nathan Lawrentschuk University of Melbourne
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Paul Mitchell
Paul Mitchell University of Sydney
Edouard C. Nice
Edouard C. Nice Monash University
David A. Reardon
David A. Reardon Harvard University
Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a variety of allied health and administrative pathways beyond just becoming a doctor. Many students look for alternative routes that can provide faster entry into the healthcare industry or offer more flexible study options.

There are easy nursing programs to get into for those who want to make a quick transition into nursing, including options with less competitive admissions. If standardized tests are a concern, some nursing programs without TEAS or HESI exam requirements offer an accessible alternative.

For those interested in healthcare administration, a variety of healthcare administration degrees are available fully online, including accelerated programs that let you complete your education quickly.

If you prefer non-clinical roles, medical billing and coding is in high demand. Many top colleges provide online certificates with medical billing and coding financial aid to support your studies.

Consider these alternative pathways as you plan your healthcare education and career journey in the USA.

Best Scientists Citing Andrew M. Scott

Trending Scientists

Recently Published Articles